Department of Neurology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
J Alzheimers Dis. 2021;79(2):607-613. doi: 10.3233/JAD-201050.
Specialized pro-resolving mediators (SPMs) are bioactive lipids derived from n-3 and n-6 polyunsaturated fatty acids. SPMs promote resolution of inflammation and are reduced in Alzheimer's disease. It is unknown whether SPMs are associated with post-stroke cognitive impairment (PSCI).
In the present report, we aimed to study the levels of SPMs in PSCI patients in the acute phase of ischemic stroke.
Levels of SPMs in the plasma from 36 patients with PSCI and 33 patients with post-stroke non-cognitive impairment (PSNCI) were measured by enzyme immunoassay.
We found that levels of the SPM lipoxin A4 (LXA4) were significantly reduced in PSCI patients compared with PSNCI patients. Interestingly, the LXA4 levels were positively correlated with Mini-Mental State Examination scores, but not with the National Institutes of Health Stroke Scale scores. Such alteration and correlation were not found in any of the other SPMs analyzed, i.e., including resolvin D1, resolvin D2, and maresin 1.
We conclude that the plasma levels of LXA4 were reduced in PSCI patents in the acute phase of ischemic stroke and were correlated to cognitive function.
特异性促解决介质（SPM）是来源于 n-3 和 n-6 多不饱和脂肪酸的生物活性脂质。SPM 可促进炎症的解决，并且在阿尔茨海默病中减少。目前尚不清楚 SPM 是否与卒中后认知障碍（PSCI）有关。
本报告旨在研究缺血性卒中急性期 PSCI 患者的 SPM 水平。
采用酶联免疫吸附法检测 36 例 PSCI 患者和 33 例卒中后非认知障碍（PSNCI）患者血浆中 SPM 的水平。
我们发现 PSCI 患者的 SPM 脂氧素 A4（LXA4）水平明显低于 PSNCI 患者。有趣的是，LXA4 水平与简易精神状态检查评分呈正相关，而与国立卫生研究院卒中量表评分无关。在分析的其他 SPM 中均未发现这种变化和相关性，包括 15-去甲氧基-11,12,13,14-前列腺素 J2（15d-PGJ2）、17-去甲氧基-11,12,13,14-前列腺素 J2（17d-PGJ2）和maresin 1。
我们得出结论，缺血性卒中急性期 PSCI 患者血浆 LXA4 水平降低，与认知功能相关。
